inclusion criteria: 1. ≥18 years 2. use of intermittent mechanical ventilation, non-invasive mechanical ventilation (nimv) or high flow nasal cannula. 3. have ards or acute lung injury physiology confirmed by pao2/fio2 ratio of \< 300 4. severe acute respiratory distress syndrome (sars) - coronavirus (cov-2) determined by lab polymerase chain reaction assay in either upper or lower respiratory tract sampling (e.g. bronchoalveolar lavage or nasopharyngeal swab) 5. if childbearing age: agree to practice effective birth control from screening until at least 180 days after last dose

inclusion criteria: 1. ≥18 years 2. use of intermittent mechanical ventilation, non-invasive mechanical ventilation (nimv) or high flow nasal cannula. 3. have ards or acute lung injury physiology confirmed by pao2/fio2 ratio of \< 300 4. severe acute respiratory distress syndrome (sars) - coronavirus (cov-2) determined by lab polymerase chain reaction assay in either upper or lower respiratory tract sampling (e.g. bronchoalveolar lavage or nasopharyngeal swab) 5. if childbearing age: agree to practice effective birth control from screening until at least 180 days after last dose

inclusion criteria: ≥18 years use of intermittent mechanical ventilation, non-invasive mechanical ventilation (nimv) or high flow nasal cannula. have ards or acute lung injury physiology confirmed by pao2/fio2 ratio of < 300 severe acute respiratory distress syndrome (sars) - coronavirus (cov-2) determined by lab polymerase chain reaction assay in either upper or lower respiratory tract sampling (e.g. bronchoalveolar lavage or nasopharyngeal swab) if childbearing age: agree to practice effective birth control from screening until at least 180 days after last dose

inclusion criteria: ≥18 years use of intermittent mechanical ventilation, non-invasive mechanical ventilation (nimv) or high flow nasal cannula. have ards or acute lung injury physiology confirmed by pao2/fio2 ratio of < 300 severe acute respiratory distress syndrome (sars) - coronavirus (cov-2) determined by lab polymerase chain reaction assay in either upper or lower respiratory tract sampling (e.g. bronchoalveolar lavage or nasopharyngeal swab) if childbearing age: agree to practice effective birth control from screening until at least 180 days after last dose

inclusion criteria: 1. ≥18 years 2. use of intermittent mechanical ventilation, non-invasive mechanical ventilation (nimv) or high flow nasal cannula. 3. have ards or acute lung injury physiology confirmed by pao2/fio2 ratio of < 300 4. severe acute respiratory distress syndrome (sars) - coronavirus (cov-2) determined by lab polymerase chain reaction assay in either upper or lower respiratory tract sampling (e.g. bronchoalveolar lavage or nasopharyngeal swab) 5. if childbearing age: agree to practice effective birth control from screening until at least 180 days after last dose

inclusion criteria: 1. ≥18 years 2. use of intermittent mechanical ventilation, non-invasive mechanical ventilation (nimv) or high flow nasal cannula. 3. have ards or acute lung injury physiology confirmed by pao2/fio2 ratio of < 300 4. severe acute respiratory distress syndrome (sars) - coronavirus (cov-2) determined by lab polymerase chain reaction assay in either upper or lower respiratory tract sampling (e.g. bronchoalveolar lavage or nasopharyngeal swab) 5. if childbearing age: agree to practice effective birth control from screening until at least 180 days after last dose